Representative Structure of PEGtide
Invention Summary:
Dentrimers and dendrons have generated tremendous interest as nanocarriers for various drug delivery applications. Rutgers scientists have developed a series of novel monodisperse PEGtide dendrons with versatility to accommodate various drug delivery demands.
PEGtide dendrons containing alternating discrete poly (ethylene glycol) (dPEG) and amino acid/peptide moieties defines a new family of dendrons with significantly improved safety, biocompatibility and purity compared to its peers. A tunable interior void size that can reaches 200nm enables PEGtide dendrons to accommodate larger agent (e.g. Nucleic acids and proteins), meeting the advanced requirements of drug delivery applications. PEGtide dendrons have a benefit of higher coupling efficiency, automation and ease of purification. Functionalization of PEGtide dendrons (e.g. Conjugation of receptor ligands) have proven their promising application in targeted therapies.
Market Applications:
- Pharmaceutical formulation for:
- Antineoplastic agents
- Antiviral agent
- Anti-inflammatory agents
- Antimicrobial agents
- Antiretroviral agents
- Vaccine
- Diagnostic agents
Advantages:
- Low cytotoxicity
- Easily functionalized for targeted therapy
- Modular design with high flexibility to accommodate various applications, such as delivery of small molecule drugs, vaccines, or oligonucleotides/siRNA
- High structural homogeneity
Intellectual Property & Development Status:
Issued patent # 9,457,099. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships contact: marketingbd@research.rutgers.edu
